Companies will partner to advance multispecific antibodies in up to seven discrete projects, including one program against an undisclosed target currently in lead selection
Invenra recently announced a collaboration with Merck to discover fully human therapeutic antibodies against an unnamed target of interest to Merck
Exelixis and Invenra will collaborate to discover and develop multispecific antibodies through the use of Invenra’s B-Body™ technology platform
